Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing

BackgroundThe role of HIV-1 RNA in the emergence of resistance to antiretroviral therapies (ARTs) is well documented while less is known about the role of historical viruses stored in the proviral DNA. The primary focus of this work was to characterize the genetic diversity and evolution of HIV drug resistant variants in an individual’s provirus during antiretroviral therapy using next generation sequencing.MethodsBlood samples were collected prior to antiretroviral therapy exposure and during the course of treatment from five patients in whom drug resistance mutations had previously been identified using consensus sequencing. The spectrum of viral variants present in the provirus at each sampling time-point were characterized using 454 pyrosequencing from multiple combined PCR products. The prevalence of viral variants containing drug resistant mutations (DRMs) was characterized at each time-point.ResultsLow abundance drug resistant viruses were identified in 14 of 15 sampling time-points from the five patients. In all individuals DRMs against current therapy were identified at one or more of the sampling time-points. In two of the five individuals studied these DRMs were present prior to treatment exposure and were present at high prevalence within the amplified and sequenced viral population. DRMs to drugs other than those being currently used were identified in four of the five individuals.ConclusionThe presence of DRMs in the provirus, regardless of their observed prevalence did not appear to have an effect on clinical outcomes in the short term suggesting that the drug resistant viral variants present in the proviral DNA do not appear to play a role in the short term in facilitating the emergence of drug resistance.

[1]  B. Schmidt,et al.  Quality Control Trial for Human Immunodeficiency Virus Type 1 Drug Resistance Testing Using Clinical Samples Reveals Problems with Detecting Minority Species and Interpretation of Test Results , 2003, Journal of Clinical Microbiology.

[2]  David L. Robertson,et al.  The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time—An Ultra-Deep Approach , 2010, PLoS Comput. Biol..

[3]  A. Trkola,et al.  HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.

[4]  John W. Mellors,et al.  Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.

[5]  Gregory S Turenchalk,et al.  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.

[6]  Kevin Dieckhaus,et al.  Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use , 2009, PloS one.

[7]  V. Calvez,et al.  Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. , 2011, The Journal of antimicrobial chemotherapy.

[8]  D. Kuritzkes,et al.  High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen , 2012, AIDS.

[9]  Drug resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural Malawi. , 2011, AIDS research and human retroviruses.

[10]  Matthias Cavassini,et al.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Hammer,et al.  Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.

[12]  Sarah Palmer,et al.  Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy , 2006, AIDS.

[13]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[14]  M. Wainberg,et al.  High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens , 2006, Antimicrobial Agents and Chemotherapy.

[15]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[16]  B. Masquelier,et al.  Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  Rodolphe Thiébaut,et al.  Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy , 2008, AIDS.

[18]  D. O’Connor,et al.  Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for Surveillance of HIV Drug Resistance , 2012, PloS one.

[19]  R. Shafer.  Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. , 2009, The Journal of infectious diseases.

[20]  M. Wainberg,et al.  Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1 , 2008, Journal of Virology.

[21]  M. Wainberg,et al.  Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. , 2009, The Journal of infectious diseases.

[22]  D. Richman,et al.  Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. , 1998, AIDS Research and Human Retroviruses.

[23]  Tommy F. Liu,et al.  Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors , 2009, Journal of acquired immune deficiency syndromes.

[24]  J. Lundeberg,et al.  Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected Using Ultra-Deep Pyrosequencing , 2010, PloS one.

[25]  Tommy F. Liu,et al.  Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation , 2010, PloS one.

[26]  Roger Paredes,et al.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.

[27]  M. Wainberg,et al.  HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture , 2006 .

[28]  M. Wainberg,et al.  A Template-Dependent Dislocation Mechanism Potentiates K65R Reverse Transcriptase Mutation Development in Subtype C Variants of HIV-1 , 2011, PloS one.

[29]  Simon A. A. Travers,et al.  Reverse transcriptase drug resistance mutations in HIV-1 subtype C infected patients on ART in Karonga District, Malawi , 2011, AIDS research and therapy.

[30]  V. Calvez,et al.  Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors , 2006, AIDS.

[31]  L. Palmisano,et al.  The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy , 2009, HIV medicine.

[32]  Cassandra B. Jabara,et al.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID , 2011, Proceedings of the National Academy of Sciences.

[33]  P. Gorry,et al.  Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  M. Plana,et al.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.

[35]  M. Ronaghi,et al.  Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.

[36]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.